Thursday, 9 June 2016

Challenges in development of DALIRESP (Roflumilast) tablet 500 MCG

Roflumilast tablet development...

(1) Particle Size Distribution of API since API is BCS class II


(2) Blend uniformity of granules due to low concentration of API

(3) Content Uniformity of tablets due to the low drug content

Post your opinion for challenges and mitigation stretagy for development of Roflumilast tablet 500 MCG.



No comments:

Post a Comment